FDA approves Pfizer's LITFULO™ (ritlecitinib) for adults and adolescents with severe alopecia areata
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Pfizer's TALZENNA® in combination with XTANDI® receives U.S. FDA approval
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Real-world evidence highlights the urgent need to act on the growing global burden of chronic kidney disease
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
Results from the REVEAL-CKD multinational study showed that the prevalence of undiagnosed Stage 3 (moderate) CKD was 85% to 97% across Spain, Australia, Canada and Brazil.
Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
Overexpression or genetic activation of Cyclin Dependent Kinase 2 (CDK2) binding partner cyclin E is a key oncogenic process in several cancers.
AstraZeneca announces agreement with Quell Therapeutics to develop, manufacture and commercialise engineered T-regulatory cell therapies for autoimmune diseases
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
Under the terms of the agreement, Quell's proprietary toolbox of Treg cell engineering modules, including its innovative Foxp3 Phenotype Lock will be leveraged to develop autologous multi-modular Treg cell therapy candidates for major autoimmune disease indications.
Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
New England Journal of Medicine publishes results from Phase 3 induction and maintenance programs evaluating upadacitinib (RINVOQ®) in Crohn's disease
- Details
- Category: AbbVie
![AbbVie AbbVie](/images/logo/abbvie.png)
More Pharma News ...
- Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer
- U.S. FDA approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in older adults
- Bayer launches unit to develop new precision health consumer products
- Pfizer's PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19
- Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI
- FDA Advisory Committee votes in support of approval for Pfizer's vaccine candidate to help prevent RSV in infants through maternal immunization
- Thermo Fisher Scientific & Pfizer partner to expand localized access to next generation sequencing-based testing for cancer patients in international markets